Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Chinese Patent Office
Julphar
Colorcon
Accenture
UBS
Chubb
Citi
Argus Health

Generated: May 27, 2018

DrugPatentWatch Database Preview

Oxamniquine - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for oxamniquine and what is the scope of oxamniquine patent protection?

Oxamniquine
is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for oxamniquine
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Bulk Api Vendors: 15
Patent Applications: 1,065
DailyMed Link:oxamniquine at DailyMed
Medical Subject Heading (MeSH) Categories for oxamniquine
Synonyms for oxamniquine
(+-)-Oxamniquine
(+)-Oxamniquine
(+/-)-Oxamniquine
(2-[(Isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydro-6-quinolinyl)methanol #
(2-{[(1-methylethyl)amino]methyl}-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol
(7-nitro-2-{[(propan-2-yl)amino]methyl}-1,2,3,4-tetrahydroquinolin-6-yl)methanol
[2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl]methanol
[7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol
{2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydro-6-quinolinyl}methanol
{2-[(Isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol
00BCY677OT
1,2,3,4-Tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-6-quinolinemethanol
1,2,3,4-Tetrahydro-2-((isopropylamino)methyl)-7-nitro-6-quinolinemethanol
1,2,3,4-Tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol
1,3,4-Tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol
119678-90-9
2-((Isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydro-6-quinolinemethanol
2-(Isopropylaminomethyl)-7-nitro-1,2,3,4-tetrahydroquinoline-6-methanol
2-(Isopropylaminomethyl)-7-nitro-1,3,4-tetrahydroquinoline-6-methanol
21738-42-1
40247-39-0
5-22-11-00475 (Beilstein Handbook Reference)
6-Hydroxymethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline
6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-
6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-, (-)-
6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-, (+)-
6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-((isopropylamino)methyl)-7-nitro-
6-Quinolinemethanol, 1,2,3,4-tetrahydro-2-[[(1-methylethyl)amino]methyl]-7-nitro-
6-Quinolinemethanol,2,3,4-tetrahydro-2-[(isopropylamino)methyl]-7-nitro-
6-Quinolinemethanol,2,3,4-tetrahydro-2-[[(1-methylethyl)amino]methyl]-7-nitro-
7GIJ138H3K
AC1L1IK1
ACM21738421
BRN 0485597
C07341
C14H21N3O3
CAS-21738-42-1
CCRIS 4113
CHEBI:78416
CHEMBL847
CTK8A2742
D00460
D0P4MT
DB01096
DSSTox_CID_3398
DSSTox_GSID_23398
DSSTox_RID_77013
DTXSID3023398
EINECS 244-556-4
HE057337
HE325620
HMS1571M13
HMS2230H11
HMS3371N13
HSDB 6510
LS-142025
Mansil
Mansil (TN)
MLS000756891
NCGC00016755-01
NSC 352888
NSC-352888
NSC352888
Oxaminiquine
Oxamniquina
Oxamniquina [INN-Spanish]
Oxamniquine (USAN/INN)
Oxamniquine [USAN:BAN:INN]
OXAMNIQUINE DISCONTINUED
Oxamniquine, (-)-
Oxamniquine, (+)-
Oxamniquinum
Oxamniquinum [INN-Latin]
Prestwick0_001026
Prestwick1_001026
Prestwick2_001026
SCHEMBL44921
SMR000528982
SPBio_003072
SR-01000765728
SR-01000765728-2
Tox21_110593
UK 4261
UK 4271
UK-4271
UNII-00BCY677OT
UNII-7GIJ138H3K
Vansil
Vansil (TN)
XCGYUJZMCCFSRP-UHFFFAOYSA-N

US Patents and Regulatory Information for oxamniquine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer VANSIL oxamniquine CAPSULE;ORAL 018069-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for oxamniquine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer VANSIL oxamniquine CAPSULE;ORAL 018069-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer VANSIL oxamniquine CAPSULE;ORAL 018069-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer VANSIL oxamniquine CAPSULE;ORAL 018069-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Covington
Dow
McKesson
Julphar
Chinese Patent Office
Teva
Healthtrust
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.